Pfizer Lays Out A Growth Plan To Offset $17bn In Coming Exclusivity Losses

Pfizer Inc. has promised investors that it will grow its current inline business (excluding foreign exchange and COVID-19 revenues) at a compound annual growth rate of 6% or higher through 2025 and that it can continue to grow through 2030 despite what is expected to be heavy headwinds from losses of exclusivity (LOEs) beginning in 2026.

Management presented the case for growth during a pipeline day on 12 December, saying new drugs from its internal pipeline along with drugs gained through business development will more than offset what is expected to be a $17bn revenue loss from LOEs in the 2025-2030 period. The company is poised to lose some of its best-selling drugs to generic and biosimilar competition in that timeframe, drugs like Eliquis (apixaban), Ibrance (palbociclib) and Xeljanz (tofacitinib)